Genmab A/S is a publicly traded company trading on NASDAQ, led by CEO Jan van de Winkel.
Upcoming earnings announcement for Genmab A/S
Past 12 earnings reports for Genmab A/S
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | Q4 2025 | $0.05Est: $0.44 | -88.6% | $1.1BEst: $4.4B | -76.0% | — |
| Nov 6, 2025 | Q3 2025 | $0.65Est: $0.46 | +40.4% | $1.0BEst: $4.2B | -75.7% | — |
| Aug 7, 2025 | Q2 2025 | $0.54Est: $0.36 | +50.6% | $925.0MEst: $3.8B | -75.8% | — |
| May 8, 2025 | Q1 2025 | $0.31Est: $0.23 | +34.8% | $715.0MEst: $748.6M | -4.5% | — |
| Feb 12, 2025 | Q4 2024 | $0.85Est: $0.28 | +203.6% | $921.6MEst: $885.3M | +4.1% | — |
| Nov 6, 2024 | Q3 2024 | $0.29Est: $0.35 | -17.1% | $816.0MEst: $828.5M | -1.5% | — |
| Aug 8, 2024 | Q2 2024 | $0.31Est: $0.33 | -6.1% | $779.5MEst: $733.2M | +6.3% | — |
| May 2, 2024 | Q1 2024 | $0.29Est: $0.14 | +107.1% | $600.4MEst: $577.5M | +4.0% | — |
| Feb 14, 2024 | Q4 2023 | $0.36Est: $4.02 | -91.0% | $675.0MEst: $679.6M | -0.7% | — |
| Nov 7, 2023 | Q3 2023 | $0.47 | — | $692.7MEst: $630.5M | +9.9% | — |
| Aug 3, 2023 | Q2 2023 | $0.30Est: $0.31 | -2.9% | $613.5MEst: $618.8M | -0.9% | — |
| May 10, 2023 | Q1 2023 | $0.05Est: $0.65 | -92.3% | $411.3MEst: $417.9M | -1.6% | — |
We use cookies for analytics. See our Privacy and Cookie Policy.